Evidence map›Paper›PMID 39664248›Full record

ArticleRSC advances2024

Biomimetic CuCoO

Mingjin Xu, Youyin Xu, Chenxi Du, Guanghui Gu, Gang Wei

Abstract read
In one paragraph

Article in RSC advances, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Mingjin XuDepartment of Radiation Oncology, The Affiliated Hospital of Qingdao University Qingdao 266700 PR China guguanghui@qdu.edu.cn.
Youyin XuCollege of Chemistry & Chemical Engineering, Qingdao University 266071 Qingdao PR China weigroup@qdu.edu.cn.
Chenxi DuCollege of Chemistry & Chemical Engineering, Qingdao University 266071 Qingdao PR China weigroup@qdu.edu.cn.
Guanghui GuDepartment of Radiation Oncology, The Affiliated Hospital of Qingdao University Qingdao 266700 PR China guguanghui@qdu.edu.cn.
Gang WeiCollege of Chemistry & Chemical Engineering, Qingdao University 266071 Qingdao PR China weigroup@qdu.edu.cn.ORCID https://orcid.org/0000-0002-3838-8659

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The flexible design and unique physical and chemical properties of self-assembled peptides have shown great potential for applications in the fields of materials science, life science, and environmental science. Peptide nanofibers (PNFs), as a kind of bioactive nanomaterials, possess excellent biocompatibility, flexible designability, and multifaceted functionalizability. In this work, we design and describe PNFs that self-assembled by peptide molecules as carriers for bimetallic nanosheets (BMNS), leading to the development of hybrid nanomaterials, BMNS-PNFs, with unique properties. The BMNS-PNFs exhibit a photothermal conversion efficiency (PCE) of up to 31.57%, and can be used as a potential nanoplatform for photothermal therapy (PTT) of lung tumour cells. Through the results, it is shown that the PNFs can reduce the cytotoxicity of BMNS-PNFs and that BMNS-PNFs have excellent cancer cell killing effects, with photothermal killing rates of more than 95% and 90% for lung cancer cells HCC2279 and PC9, respectively. Finally, the comprehensive PTT performance of BMNS-PNFs is analysed by Ranking of Efficiency Performance (REP), and the REP value of BMNS-PNFs is calculated to be 0.741. The peptide sequences used to assemble into PNFs in this study are instructive for functional design and structural modulation of molecular self-assembly, and the constructed bimetallic-biomolecular hybrid materials provide a potential strategy for medical bioengineering.

Identifiers

PMID39664248
PMCPMC11632949

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.